This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
by Zacks Equity Research
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Biotech ETF (CANC) Hits New 52-Week High
by Sanghamitra Saha
CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.
Here's Why Biotech ETFs Are Rallying Hard
by Sanghamitra Saha
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Be Thankful to These ETFs This Year
by Sanghamitra Saha
Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.
Inside the Recent Strength in Biotech ETFs
by Sanghamitra Saha
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Biotech ETFs Bounce Back in 2025: Here's Why
by Sanghamitra Saha
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
by Neena Mishra
We discuss attractive investment opportunities within the healthcare industry.